Bank of America
ARTV

Bank of America’s Artiva Biotherapeutics ARTV Stock Holding History

Bank of America’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-113
Closed -$484 – 7048
2025
Q4 		$484 Sell
113
-16,032
-99% -$60.6K ﹤0.01% 6564
2025
Q3 		$46.3K Buy
16,145
+11,190
+226% +$29.9K ﹤0.01% 6860
2025
Q2 		$7.48K Sell
4,955
-3,341
-40% -$7.02K ﹤0.01% 7240
2025
Q1 		$24.9K Sell
8,296
-2,521
-23% -$13.6K ﹤0.01% 6910
2024
Q4 		$109K Sell
10,817
-7,001
-39% -$84.1K ﹤0.01% 6354
2024
Q3 		$275K Buy
+17,818
New +$206K ﹤0.01% 5857

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Bank of America's ARTV Position: Q1 2026 in Review

Bank of America sold out of Artiva Biotherapeutics (ARTV) in Q1 2026, closing a stake of 113 shares — an estimated $484 sold.

Bank of America first reported a position in ARTV in Q3 2024 and held it in 6 quarters. The position peaked at $275K in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Bank of America reported no remaining Artiva Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 113 Artiva Biotherapeutics shares in Q1 2026, an estimated $484.
  • Bank of America first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 6 quarters.
  • Bank of America's Artiva Biotherapeutics position peaked at $275K in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.